FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points Pursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitability Announces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transition BURLINGTON, Mass. , Nov.
12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA ) today reported financial results for the fourth quarter and fiscal year ended September 30, 2024 . Fiscal Year 2024 Highlights: Q4'24 revenue growth of 6% reported and 5% organic, in combined Sample Management Solutions and Multiomics FY'24 Adjusted EBITDA margin expansion of approximately 300 basis points versus last year Management Comments "We ended fiscal 2024 strong, delivering core revenue growth in our Sample Management Solutions and Multiomics businesses, and upholding our commitment to meaningfully expand margins," stated John Marotta , President and CEO.
"We are proud of the progress that we made in fiscal 2024, particularly in our Transformation Program Ascend 2026, and intend to carry that momentum forward to drive further performance, as proven by our fiscal 2025 guidance, which anticipates core revenue growth in the range of 3% to 5%, with continued margin expansion and a renewed focus on free cash flow." Mr. Marot.